Paraxanthine Naringenin Co-crystal

Paraxanthine Naringenin Co-crystal
Product Name: Paraxanthine Naringenin Co-crystal
Purity: ≥ 99.0% HPLC
Assay: ≥ 99.0% HPLC
Appearance: Off-White Powder
Certification: ISO9001/FSSC22000/HALAL/KOSHER
GRAS Status: SA-GRAS Certification in Progress
US Patent Application Pending

WHAT IS PARAXANTHINE NARINGENIN CO-CRYSTAL?

 

Paraxanthine Naringenin Co-crystal brings paraxanthine and naringenin together in a new crystalline form. Youyou Biotechnology offers this ingredient for brands and manufacturers exploring differentiated formulations, with a manufacturer-described taste advantage and preliminary rat pharmacokinetic data for technical evaluation.

 

Scientific Principle

Cocrystal design  

 

The product is described as a co-crystal with its own solid-state identity, rather than a physical blend of two powders. Development therefore considers the crystal form together with taste, dispersion and performance in the finished formula. NMR provides chemical characterization; crystal-phase identity should be assessed with suitable solid-state methods. 

 

Paraxanthine pathways  

 

Paraxanthine is a principal metabolite of caffeine. Its antagonism of adenosine A1 and A2A receptors provides a mechanistic basis for research into wakefulness, attention and perceived fatigue. The product brochure also describes PDE and cAMP pathways as metabolic research background. These mechanisms do not establish the effects of this co-crystal in humans. 

Benefits and Scientific Support

Energy and focus research 

 

Published human research on paraxanthine has examined selected measures of cognition and attention. This supports the rationale for exploring energy and focus formulations, while product-specific efficacy requires evidence for the co-crystal itself. 

 

Taste focused development  

 

The manufacturer describes the ingredient as having no bitterness. This makes sensory evaluation relevant to beverages, oral pouches and gummies. Confirm taste acceptance at the intended use level and in the complete formula. 

 

Rat pharmacokinetic comparison

  

In the supplied rat study, the co-crystal group showed higher measured paraxanthine exposure under the listed study conditions. The measured analyte was paraxanthine, with six animals in each group. 

 

Paramete

Paraxanthine

Co-crystal

Listed dose (mg/kg)

20

35.1

AUC (ng·h/mL)

117,198 ± 26,661

188,421 ± 50,498

Cmax (ng/mL)

22,622 ± 8,585

32,427 ± 9,899

Half life (h)

2.00 ± 0.130

1.80 ± 0.160

Median Tmax (h)

0.5

1.0

Observed AUC ratio

1.00

1.61

 

Values are mean ± SD unless stated otherwise. The observed AUC ratio is approximately 1.61, or 61% higher exposure. The listed doses differ and the paraxanthine-equivalent dose basis is unconfirmed; this is not a verified dose-normalized bioavailability improvement or a human absorption result. Administration route and sample matrix are not specified. 

 

Analytical and water behavior information  

 

The dossier includes an NMR spectrum and photographs after standing and stirring. These materials support further evaluation; the photographs alone do not quantify solubility, dissolution rate or long-term stability.

Applications

Potential development formats include beverages and powdered drink mixes, oral pouches, gummies and capsules. Evaluate taste, dispersion, processing compatibility and storage stability in each intended formula. These are development concepts, subject to technical assessment and applicable market requirements.

Suggested Dosage

Formulation use levels should be selected using product-specific safety information, confirmed component assays and the requirements of the intended application. Rat study doses should not be used as a consumer dosage recommendation.

FAQ

Inquiry

+86-180 6194 3023sales@uubiotech.com
Let's Create New Trends
Have further questions? Our friendly experts will get back to you within 24 hours to assist you further.
Partner with us